Genomic Predictors of Recurrent Pregnancy Loss
Yale University · with Johns Hopkins University, University of Texas at Austin · NCT05444283
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 500
- US sites recruiting
- 9
- Study start
- September 1, 2021
- Record last updated
- May 22, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Conditions: Recurrent Pregnancy Loss
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Cohort A - Fetal Intolerome Cohort
Inclusion Criteria
- Women with loss of a current singleton pregnancy at \< 20 0/7 weeks gestation, documented by ultrasonography or histopathological examination
- History of one or more prior pregnancy losses
- Euploid current pregnancy confirmed by karyotype, microarray, or STORK (Short-read Transpore Rapid Karyotyping) sequencing Note: A limited number of aneuploid losses will be included as part of the pilot phase
Exclusion Criteria
- History of parental karyotype abnormalities
- History of antiphospholipid antibody syndrome
- Evidence of uncontrolled diabetes
- Evidence of uncontrolled thyroid disease
- History of autoimmune disease related to pregnancy loss (e.g., systemic lupus erythematosus, rheumatoid arthritis)
- History of uterine anomalies
- History of cervical insufficiency
Cohort B - Maternal Effect Gene Cohort
Inclusion Criteria
- Women with a history of three or more pregnancy losses of unknown cause, with or without a liveborn child
Exclusion Criteria
- Known etiology for pregnancy loss
Recruiting US locations
University of Colorado
Aurora, CO 80045
Site contact: Asma Giornazi, MS · 720-276-8941 · asma.giornazi@ucdenver.edu
Yale University
New Haven, CT 06511
Site contact: Yong-Hui Jiang, MD, PhD · 203-785-2429 · yong-hui.jiang@yale.edu
Northwestern University
Chicago, IL 60611
Site contact: Riley Bonaccorsi · 312-694-6678 · riley.bonaccorsi@nm.org
Johns Hopkins University
Baltimore, MD 21205
Site contact: Samya El Sayed, MD · 443-473-2674 · selsaye4@jh.edu
Wayne State University
Detroit, MI 48201
Site contact: Michelle Yoscovits · 313-577-8016 · mbrossoi@med.wayne.edu
Columbia University
New York, NY 10032
Site contact: Jessica Giordano, CGC · 516-521-5604 · jlg2197@cumc.columbia.edu
Pennsylvania State University
Hershey, PA 17033
Site contact: Robinn Moyer · 717-531-6272 · Rmoyer3@pennstatehealth.psu.ed
University of Texas at Austin
Austin, TX 78712
Site contact: Elizabeth Davis, RN · 512-495-2103 · elizabethrose.davis@austin.utexas.edu
University of Texas at San Antonio
San Antonio, TX 78299
Site contact: Susie Reyes, RN · 210-450-5384 · reyessr@uthscsa.edu
Study contacts (from the official record)
- Yong-Hui Jiang, MD, PhD · 2037852429 · yong-hui.jiang@yale.edu
- Heping Zhang, PhD · 12037855185 · heping.zhang@yale.edu
Similar studies in Colorado
All pregnancy studies in Colorado →- RecruitingHealthy volunteersPhase 1
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development
University of Colorado, Denver
- Location
- Aurora, CO
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingHealthy volunteersPhase 3
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Pfizer
- Location
- Aurora, CO + 76 other US sites
- Eligibility basics
- Ages 0 mo+
- RecruitingHealthy volunteersPhase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Pfizer
- Location
- Aurora, CO + 111 other US sites
- Eligibility basics
- Ages 0 mo–49
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Aurora, CO + 21 other US sites
- Eligibility basics
- Ages 2–17